ARTES Biotechnology and Bio Farma have collaborated to develop and manufacture vaccine candidates.
As part of the mutually agreed collaboration, both companies have already signed a first agreement for virus-like particles (VLP) based vaccine technology transfer in Bandung, Indonesia.
ARTES’s Metavax patent protected VLP technology has been designed to develop and produce safe and cost-effective vaccines, claimed the company.
When compared to other existing VLP approaches in the market, Metavax platform provides a highly potent immune response and enhanced protection as it is based on modifications to duck hepatitis B virus.
ARTES Biotechnology founder and managing director Dr Michael Piontek said Bio Farma is a reliable pharmaceutical partner and the only vaccine and antisera producer for humans in Indonesia.
"We are more than confident, that we along with Bio Farma will develop vaccines highly relevant for the Indonesian and neighboring markets," Piontek said.
"We expect that especially developments based on our Metavax technology will contribute to Bio Farma’s vaccine portfolio."
The commitment is fully supported by the Indonesian Government, including assistance in the area of policy-making to help speed up the process of developing vaccines in the country.
ARTES specialises in cell line and process development, VLP based vaccines in addition to in-technology transfer for pharmaceutically relevant production processes.
Bio Farma is involved in the manufacturing of vaccines, serum and other biological products for the Indonesian domestic and international markets.
Image: Bio Farma is only vaccine and antisera producer for humans in Indonesia. Photo: courtesy of Guzoer.
